Welcome to our dedicated page for Greenland Mines Warrant (formerly Klotho Neurosciences) SEC filings (Ticker: KLTOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Greenland Mines Warrant (formerly Klotho Neurosciences)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Greenland Mines Warrant (formerly Klotho Neurosciences)'s regulatory disclosures and financial reporting.
Klotho Neurosciences, Inc. has amended and restated its definitive proxy to change the record and special meeting dates and to seek stockholder approval for several capital actions. The February 17, 2026 virtual Special Meeting will ask investors to approve a reverse stock split of common stock at a ratio between one-for-2 and one-for-50, at the Board’s discretion, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price and potentially broaden institutional interest. Stockholders will also vote on increasing the reserve under the 2024 Equity Incentive Plan to 10,000,000 shares of common stock and on a proposal allowing adjournment of the meeting to solicit additional proxies if needed. As of January 15, 2026, the company had 73,536,722 common shares outstanding, and directors and executive officers as a group beneficially owned 7,303,632 shares.
Klotho Neurosciences, Inc. has amended and restated its definitive proxy to change the record and special meeting dates and to seek stockholder approval for several capital actions. The February 17, 2026 virtual Special Meeting will ask investors to approve a reverse stock split of common stock at a ratio between one-for-2 and one-for-50, at the Board’s discretion, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price and potentially broaden institutional interest. Stockholders will also vote on increasing the reserve under the 2024 Equity Incentive Plan to 10,000,000 shares of common stock and on a proposal allowing adjournment of the meeting to solicit additional proxies if needed. As of January 15, 2026, the company had 73,536,722 common shares outstanding, and directors and executive officers as a group beneficially owned 7,303,632 shares.
Klotho Neurosciences, Inc. is calling a virtual special stockholder meeting on February 13, 2026 to vote on several capital structure proposals. The company is seeking authority to implement a reverse stock split of its common stock in a range from 1‑for‑2 to 1‑for‑50, with the exact ratio and timing to be chosen by the board any time up to June 30, 2026. The main goal is to raise the share price to meet Nasdaq’s $1.00 minimum bid requirement and support continued listing on The Nasdaq Capital Market.
Stockholders will also vote on amending the 2024 Equity Incentive Plan to increase the maximum shares available for awards to 10,000,000, up by 8,331,874 shares, which the board says is needed to attract, retain, and motivate employees and directors. As context, the company had 73,536,722 common shares outstanding as of January 13, 2026, and current plan capacity represents about 2% of that total versus about 13.3% if the new limit is fully available. A third proposal would allow adjournment of the meeting to solicit more proxies if needed.
Klotho Neurosciences, Inc. is calling a virtual special stockholder meeting on February 13, 2026 to vote on several capital structure proposals. The company is seeking authority to implement a reverse stock split of its common stock in a range from 1‑for‑2 to 1‑for‑50, with the exact ratio and timing to be chosen by the board any time up to June 30, 2026. The main goal is to raise the share price to meet Nasdaq’s $1.00 minimum bid requirement and support continued listing on The Nasdaq Capital Market.
Stockholders will also vote on amending the 2024 Equity Incentive Plan to increase the maximum shares available for awards to 10,000,000, up by 8,331,874 shares, which the board says is needed to attract, retain, and motivate employees and directors. As context, the company had 73,536,722 common shares outstanding as of January 13, 2026, and current plan capacity represents about 2% of that total versus about 13.3% if the new limit is fully available. A third proposal would allow adjournment of the meeting to solicit more proxies if needed.